Country Market Entry Reports
Quarterly, data-driven reports designed to support clinical trial market entry decisions across European countries.
Q2 2026Updated quarterlyEU Clinical Research
Structured analysis
Each report follows a consistent methodology across all countries.
Data-driven insights
Built on live clinical trial data from EU and global registries.
Quarterly updates
Reports are refreshed every quarter with the latest activity data.
Free access
One country sample report per user is available at no cost.
Report overview
What this report includes
Each report provides a structured analysis of a country's clinical trial landscape, combining activity data, recruitment dynamics, therapeutic focus, and sponsor ecosystem.
- check_circle Clinical trial activity and market size (number of trials, growth, trends)
- check_circle Patient recruitment dynamics and enrolment capacity
- check_circle Therapeutic landscape across disease areas and indications
- check_circle Sponsor activity, including new entrants and returning sponsors
- check_circle Distribution of trials by phase and development stage
- check_circle Geographic distribution of clinical trial activity across key cities
Report contents
- 01 Executive Summary & Recommendation
- 02 Market Overview & Pipeline Intelligence
- 03 Patient Population Intelligence
- 04 Therapeutic Landscape
- 05 Rare Disease Intelligence
- 06 Sponsor Landscape & Vendor Ecosystem
- 07 Sponsor Quarterly Activity
- 08 Research Sites & Principal Investigators
- 09 Geographic Distribution
- 10 Methodology & Scoring
Example: Poland — Q1 2026
A preview of selected insights from one of our country reports.
Country Market Entry Report
Clinical Trial Market Entry: Poland
Market readiness, site infrastructure, and strategic entry analysis
April 2026EU Clinical Research25 pagesHigh Confidence
Report Summary
Growing reliance on Central and Eastern European markets for Phase II and III clinical development has renewed strategic interest in Poland as a primary country of choice. Poland's combination of regulatory efficiency, investigator depth, and established sponsor relationships positions it as one of Europe's most reliable clinical trial markets — accounting for 22.9% of all European trial activity and ranking #5 among 29 tracked nations.
Poland achieves a GO recommendation with a score of 84/100 — reflecting perfect scores on Regulatory Environment (20/20) and Sponsor Ecosystem (20/20), with 2,436 active trials across 13 cities and Phase III trials dominating at 60.1%.
Key Finding 1 of 3
Market entry score across five dimensions
Key findings
- Perfect 20/20 on Regulatory Environment — the strongest result across all tracked European markets, reflecting fast and predictable ethics committee approvals.
- Sponsor Ecosystem also 20/20: MSD (151 trials), AstraZeneca (129), Roche (120) and Janssen (97) are the four most active global sponsors.
- 84/100 overall places Poland in the GO tier (75–100) with High Confidence — the strongest entry recommendation issued by CTIN.
Key Finding 2 of 3
Trial activity by therapeutic area — top 8 of 26 disease categories
Key findings
- Neoplasms lead at 56% (1,364 trials) — non-small cell lung cancer (112), malignant neoplasms (41), and breast cancer (37) are the top three indications.
- Rare diseases account for 23.3% of all trials (568 studies) covering 335 unique conditions, confirming Poland as a significant rare disease research hub.
- Shannon diversity index of 3.93/4.70 (84% evenness) — 12 of 26 disease categories each represent ≥5% of trials, meaning no single area dominates.
Key Finding 3 of 3
Quarterly trial starts and recruitment activation — last four quarters
Key findings
- Recruitment activation rose from 78.2% in Q2 2025 to 100% in Q1 2026 — every new trial started this quarter is already recruiting or approved to do so.
- 33.9% of all 2,436 trials are actively recruiting, with a further 8.8% not yet recruiting — a combined active pipeline of 71,027 planned patients.
Why this report matters
How this report supports decision-making
The report provides a consistent, data-driven view of national clinical trial environments, supporting strategic planning and market evaluation.
Assess clinical trial activity in a specific country
Understand recruitment dynamics and patient availability
Identify therapeutic areas with high activity
Evaluate sponsor presence and market engagement
Need a report tailored to your programme?
Tell us the countries and therapeutic areas you care about, and we'll put together a custom report.